Acceleration Therapeutics

Acceleration Therapeutics is a clinical-stage biotechnology company focused on the rapid development of high-potential oncology assets. The company utilizes a "search and develop" model, identifying clinical-stage candidates with established safety profiles and clear regulatory paths to accelerate their path to market. Their lead candidate, AT-192, is a selective STAT3 inhibitor currently being investigated for the treatment of advanced solid tumors. The leadership team consists of seasoned pharmaceutical executives with a track record of successful drug approvals and commercialization. By focusing on de-risked assets and efficient clinical trial designs, the company aims to bring new cancer treatments to patients more quickly than traditional development models.